Cancer Research Annual Meeting 2010  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Akazawa, T.
Right arrow Articles by Seya, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akazawa, T.
Right arrow Articles by Seya, T.
[Cancer Research 64, 757-764, January 15, 2004]
© 2004 American Association for Cancer Research


Immunology

Adjuvant-Mediated Tumor Regression and Tumor-Specific Cytotoxic Response Are Impaired in MyD88-Deficient Mice

Takashi Akazawa1, Hisayo Masuda1, Yoshiko Saeki1, Misako Matsumoto1,5, Kiyoshi Takeda2, Kunio Tsujimura3, Kiyotaka Kuzushima3, Toshitada Takahashi3, Ichiro Azuma4, Shizuo Akira2, Kumao Toyoshima1 and Tsukasa Seya1,5

1 Department of Immunology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka;
2 Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, Osaka;
3 Division of Immunology, Aichi Cancer Center Research Institute, Nagoya;
4 Hakodate National College of Technology, Hakodate; and
5 Organization for Pharmaceutical Safety and Research, Tokyo, Japan

The Mycobacterium bovis bacillus Calmette-Guérin cell-wall skeleton (BCG-CWS) activates Toll-like receptor (TLR) 2 and TLR4, but unlike the typical TLR4 agonist bacterial lipopolysaccharide barely induces type 1 IFN. BCG-CWS has been used for adjuvant immunotherapy for patients with cancer. We investigated the adjuvant potential of BCG-CWS for induction of CTLs subsequent to TLR-mediated dendritic cell (DC) maturation, using a syngeneic mouse tumor model (B16 melanoma in C57BL/6). We evaluated the retardation of tumor growth and cytotoxic response in wild-type and MyD88-/- mice immunized with tumor debris and/or BCG-CWS. Delays in tumor growth and cytotoxic response were induced by immunization with a mixture of BCG-CWS emulsion and the tumor. BCG-CWS was capable of activating DCs ex vivo by the criteria of CD80/CD86 up-regulation and cytokine (interleukin-12, tumor necrosis factor-{alpha}) induction. Efficient tumor suppression and ex vivo cytokine induction did not occur in MyD88-deficient mice and cells, suggesting that the MyD88 adapter is crucial for induction of tumor cytotoxicity. Because TLR4 is involved in both MyD88-dependent and -independent pathways and the latter affects DC maturation, our findings indicate that both pathways cooperate to induce CTL-based tumor immunity.




This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
M. H. W. Laird, S. H. Rhee, D. J. Perkins, A. E. Medvedev, W. Piao, M. J. Fenton, and S. N. Vogel
TLR4/MyD88/PI3K interactions regulate TLR4 signaling
J. Leukoc. Biol., June 1, 2009; 85(6): 966 - 977.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Zeng, H. Li, Y. Liu, Z. Zhang, Y. Zhang, and R. Yang
Tumor-Induced Suppressor of Cytokine Signaling 3 Inhibits Toll-like Receptor 3 Signaling in Dendritic Cells via Binding to Tyrosine Kinase 2
Cancer Res., July 1, 2008; 68(13): 5397 - 5404.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Shime, M. Yabu, T. Akazawa, K. Kodama, M. Matsumoto, T. Seya, and N. Inoue
Tumor-Secreted Lactic Acid Promotes IL-23/IL-17 Proinflammatory Pathway
J. Immunol., June 1, 2008; 180(11): 7175 - 7183.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
V. Andreani, G. Gatti, L. Simonella, V. Rivero, and M. Maccioni
Activation of Toll-like Receptor 4 on Tumor Cells In vitro Inhibits Subsequent Tumor Growth In vivo
Cancer Res., November 1, 2007; 67(21): 10519 - 10527.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
T. Akazawa, T. Ebihara, M. Okuno, Y. Okuda, M. Shingai, K. Tsujimura, T. Takahashi, M. Ikawa, M. Okabe, N. Inoue, et al.
Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells
PNAS, January 2, 2007; 104(1): 252 - 257.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. E. Alvarez, J. I. F. Bass, J. R. Geffner, P. X. F. Calotti, M. Costas, O. A. Coso, R. Gamberale, M. E. Vermeulen, G. Salamone, D. Martinez, et al.
Neutrophil Signaling Pathways Activated by Bacterial DNA Stimulation
J. Immunol., September 15, 2006; 177(6): 4037 - 4046.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Sfondrini, A. Rossini, D. Besusso, A. Merlo, E. Tagliabue, S. Menard, and A. Balsari
Antitumor Activity of the TLR-5 Ligand Flagellin in Mouse Models of Cancer.
J. Immunol., June 1, 2006; 176(11): 6624 - 6630.
[Abstract] [Full Text] [PDF]


Home page
Evid Based Complement Alternat MedHome page
T. Seya, T. Akazawa, T. Tsujita, and M. Matsumoto
Role of Toll-like Receptors in Adjuvant-Augmented Immune Therapies.
Evid. Based Complement. Altern. Med., March 1, 2006; 3(1): 31 - 38.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Shingai, N. Inoue, T. Okuno, M. Okabe, T. Akazawa, Y. Miyamoto, M. Ayata, K. Honda, M. Kurita-Taniguchi, M. Matsumoto, et al.
Wild-Type Measles Virus Infection in Human CD46/CD150-Transgenic Mice: CD11c-Positive Dendritic Cells Establish Systemic Viral Infection
J. Immunol., September 1, 2005; 175(5): 3252 - 3261.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Uehori, K. Fukase, T. Akazawa, S. Uematsu, S. Akira, K. Funami, M. Shingai, M. Matsumoto, I. Azuma, K. Toyoshima, et al.
Dendritic Cell Maturation Induced by Muramyl Dipeptide (MDP) Derivatives: Monoacylated MDP Confers TLR2/TLR4 Activation
J. Immunol., June 1, 2005; 174(11): 7096 - 7103.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.